Functional assays revealed that knockdown of INCENP suppressed glioma cell proliferation, migration, and invasion while promoting apoptosis, whereas NCAPG silencing impaired migration and invasion.<h4>Conclusion</h4>This study establishes the RLPI as a promising biomarker for personalized risk stratification and treatment guidance in LGG. The gene discussed is INCENP; the disease is central nervous system cancer.